Biotech Values

[biocqr]

MRKR > ASCO abstract denied...

http://archive.fast-edgar.com//20190417/A3ATEQ2CZC223ZZZ2R2S2ZZG7GQTZB22Z2B2/

Marker Therapeutics, Inc. (“Marker” or the “Company”) previously communicated its understanding that Baylor College of Medicine (“BCM”) clinicians would present initial clinical data with our MultiTAA T cell therapy in pancreatic cancer in the second quarter at the upcoming American Society of Clinical Oncology (“ASCO”) meeting. BCM submitted its abstract to ASCO’s Trials in Progress (“TIP”) track. As ASCO’s rules prohibit the inclusion of clinical outcome data in TIP abstract submissions, BCM’s clinical trial design abstract did not include any clinical data. The abstract was not accepted by ASCO.

Marker now expects to report more mature data from the BCM’s ongoing pancreatic study in the third quarter.

Trials in Progress Abstract Submission Guidelines

https://meetings.asco.org/am/trials-progress-abstract-submission-guidelines

Preclinical and/or earlier-phase clinical data that have already been publicly presented or published may be included with references. The Trials in Progress abstract should not be used to present preclinical or earlier-phase clinical data for the first time